Product Description
TRIA-662 (1-methylnicotinamide chloride, 1-MNA chloride) is a naturally occurring, major metabolite of nicotinic acid and a nicotinamide, two main forms of the B3vitamin. (Sourced from: http://cortria.com)
Mechanisms of Action: nAChR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Cortria
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Hyperlipoproteinemias|Hyperlipidemia
Phase 2: Hypertriglyceridemia|Hyperlipoproteinemia Type V|Hyperlipoproteinemias|Hyperlipidemia|Lipidoses
Phase 1: Healthy Volunteers|Hypertension|Body Temperature Changes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 1-methylnicotinamide Chloride | P2 |
Completed |
Hypertriglyceridemia|Hyperlipidemia|Lipidoses|Hyperlipoproteinemias|Hyperlipoproteinemia Type V |
2015-10-01 |
|
| BPSI-1479 | P1 |
Completed |
Healthy Volunteers |
2013-05-01 |
|
| Cortria-001 | P3 |
Completed |
Hyperlipoproteinemias|Hyperlipidemia |
2008-12-01 |
|
| Cortria-002 | P1 |
Completed |
Body Temperature Changes|Hypertension |
2008-01-01 |